Market Overview:
The global plasma protein therapeutics market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, and technological advancements in the field of plasma protein therapeutics. Based on type, the global plasma protein therapeutics market is segmented into coagulation factor, immune globulin, albumin, and others. Coagulation factor dominates the market owing to its high usage in hemophilia treatment. Immune globulin is projected to grow at a highest CAGR during the forecast period due to its increasing demand for treating PID and other autoimmune disorders. Albumin helds a major share of this market due its extensive use as a volume expander and blood substitute across various applications such as surgery and critical care settings. Other segments include therapeutic proteins used for conditions such as burns, shock therapy etc., which are expected to register moderate growth during the forecast period owing their limited use so far as compared with other types segments mentioned earlier. Based on application, hemophilia accounts for majority share of this market followed by PID (primary immunodeficiency disease) and others including GBS (Guillain-Barre Syndrome), Crohn’s disease etc.).
Product Definition:
Plasma protein therapeutics are drugs derived from human blood plasma. They are used to treat a variety of diseases, including cancer, hemophilia, and autoimmune disorders. Plasma protein therapeutics are important because they can effectively treat a wide range of diseases.
Coagulation Factor:
Coagulation factor is a protein that promotes the coagulation of blood. It's also known as prothrombin. Coagulation factors are used in various medical applications such as hemostasis (cessation of bleeding) and treatment of diseases associated with blood clotting such as hemophilia A and B, Von Willebrand disease (VWD), and hyper-coAGULATION syndrome Xa inhibitors deficiency.
Immune Globulin:
Immune Globulin (IG) is a protein-based immunoglobulin used in the treatment of immune deficiencies. It is also used as an adjunctive therapy for cancer and autoimmune diseases. The product has been approved by the U.
Application Insights:
On the basis of application, the global market has been segmented into hemophilia, primary immunodeficiency diseases (PID), other diseases and disorders involving plasma protein therapeutics, and others. Primary immunodeficiency diseases include more than 200 rare genetic conditions that result in a reduced ability to fight infections due to a defect in the immune system. These conditions are passed from parents to children through families where there is no history of such disease. PID affects around 6 million individuals globally and about 1% of adults are estimated to be carriers of one or more gene mutations that lead to development of this condition.
The other applications segment includes cancer treatment using plasmapheresis as well as kidney transplantation procedures involving administration of antilymphocyte antibodies for treating chronic renal failure or nephrotic syndrome stages 3 & 4 patients suffering from chronic kidney failure undergoing dialysis therapy along with their healthy donors).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, favorable reimbursement scenario, and high healthcare expenditure in this region. The U.S.-based companies are involved in extensive research activities to develop novel therapies for plasma protein therapeutics production and improvement of existing manufacturing processes.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to factors such as improving healthcare infrastructure, rising disposable income coupled with growing population especially in India & China that accounts for a large part of the regional demand due to higher prevalence rate of immune disorders compared with other regions as well as lower cost associated with it making it an attractive target market for pharmaceutical companies operating within this region along with others such as Australia & New Zealand who have high unmet clinical needs resulting from lack or inadequate response by adaptive immunity against various infectious diseases thus creating a huge opportunity space within Asia Pacific Plasma Protein Therapeutics Market for new product development.
Growth Factors:
- Increasing incidence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. According to a study by the World Health Organization (WHO), non-communicable diseases (NCDs) such as heart disease, stroke, cancer, and diabetes account for more than 60% of all deaths worldwide. This is expected to drive the demand for plasma protein therapeutics in the coming years.
- Growing awareness about plasma protein therapies: There is a growing awareness among patients and healthcare professionals about the benefits of plasma protein therapies. This has led to an increase in demand for these therapies in recent years.
- Technological advancements: The development of new technologies has helped improve the efficacy and safety profile of plasma protein therapeutics products over traditional treatments options available in the market today .This is likely to boost growth prospects for this market overthe forecast period .
Scope Of The Report
Report Attributes
Report Details
Report Title
Plasma Protein Therapeutics Market Research Report
By Type
Coagulation Factor, Immune Globulin, Albumin, Others, Plasma Protein Therapeutic
By Application
Hemophilia, PID, Others
By Companies
Shire (Baxalta), CSL, Grifols, Octapharma, Kedrion, LFB Group, Biotest, BPL, RAAS, CBPO, Hualan Bio, Kamada, Plasma Protein Therapeutic
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Plasma Protein Therapeutics Market Report Segments:
The global Plasma Protein Therapeutics market is segmented on the basis of:
Types
Coagulation Factor, Immune Globulin, Albumin, Others, Plasma Protein Therapeutic
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hemophilia, PID, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Shire (Baxalta)
- CSL
- Grifols
- Octapharma
- Kedrion
- LFB Group
- Biotest
- BPL
- RAAS
- CBPO
- Hualan Bio
- Kamada
- Plasma Protein Therapeutic
Highlights of The Plasma Protein Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Coagulation Factor
- Immune Globulin
- Albumin
- Others
- Plasma Protein Therapeutic
- By Application:
- Hemophilia
- PID
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Plasma Protein Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Plasma protein therapeutics is a new and rapidly growing field of biomedical research that focuses on the use of plasma proteins to treat diseases. Plasma proteins are important components of the blood and can be used to treat a variety of medical conditions.
Some of the key players operating in the plasma protein therapeutics market are Shire (Baxalta), CSL, Grifols, Octapharma, Kedrion, LFB Group, Biotest, BPL, RAAS, CBPO, Hualan Bio, Kamada, Plasma Protein Therapeutic.
The plasma protein therapeutics market is expected to grow at a compound annual growth rate of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Plasma Protein Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Plasma Protein Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Plasma Protein Therapeutics Market - Supply Chain
4.5. Global Plasma Protein Therapeutics Market Forecast
4.5.1. Plasma Protein Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Plasma Protein Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Plasma Protein Therapeutics Market Absolute $ Opportunity
5. Global Plasma Protein Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Plasma Protein Therapeutics Market Size and Volume Forecast by Type
5.3.1. Coagulation Factor
5.3.2. Immune Globulin
5.3.3. Albumin
5.3.4. Others
5.3.5. Plasma Protein Therapeutic
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Plasma Protein Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Plasma Protein Therapeutics Market Size and Volume Forecast by Application
6.3.1. Hemophilia
6.3.2. PID
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Plasma Protein Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Plasma Protein Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Plasma Protein Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Plasma Protein Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Plasma Protein Therapeutics Demand Share Forecast, 2019-2026
9. North America Plasma Protein Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Plasma Protein Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Plasma Protein Therapeutics Market Size and Volume Forecast by Application
9.4.1. Hemophilia
9.4.2. PID
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Plasma Protein Therapeutics Market Size and Volume Forecast by Type
9.7.1. Coagulation Factor
9.7.2. Immune Globulin
9.7.3. Albumin
9.7.4. Others
9.7.5. Plasma Protein Therapeutic
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Plasma Protein Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Plasma Protein Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Plasma Protein Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Plasma Protein Therapeutics Market Size and Volume Forecast by Application
10.4.1. Hemophilia
10.4.2. PID
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Plasma Protein Therapeutics Market Size and Volume Forecast by Type
10.7.1. Coagulation Factor
10.7.2. Immune Globulin
10.7.3. Albumin
10.7.4. Others
10.7.5. Plasma Protein Therapeutic
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Plasma Protein Therapeutics Demand Share Forecast, 2019-2026
11. Europe Plasma Protein Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Plasma Protein Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Plasma Protein Therapeutics Market Size and Volume Forecast by Application
11.4.1. Hemophilia
11.4.2. PID
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Plasma Protein Therapeutics Market Size and Volume Forecast by Type
11.7.1. Coagulation Factor
11.7.2. Immune Globulin
11.7.3. Albumin
11.7.4. Other
11.7.5. Plasma Protein Therapeutic
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Plasma Protein Therapeutics Demand Share, 2019-2026
12. Asia Pacific Plasma Protein Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Plasma Protein Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Plasma Protein Therapeutics Market Size and Volume Forecast by Application
12.4.1. Hemophilia
12.4.2. PID
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Plasma Protein Therapeutics Market Size and Volume Forecast by Type
12.7.1. Coagulation Factor
12.7.2. Immune Globulin
12.7.3. Albumin
12.7.4. Others
12.7.5. Plasma Protein Therapeutic
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Plasma Protein Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Plasma Protein Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Plasma Protein Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Plasma Protein Therapeutics Market Size and Volume Forecast by Application
13.4.1. Hemophilia
13.4.2. PID
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Plasma Protein Therapeutics Market Size and Volume Forecast by Type
13.7.1. Coagulation Factor
13.7.2. Immune Globulin
13.7.3. Albumin
13.7.4. Others
13.7.5. Plasma Protein Therapeutic
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Plasma Protein Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Plasma Protein Therapeutics Market: Market Share Analysis
14.2. Plasma Protein Therapeutics Distributors and Customers
14.3. Plasma Protein Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Shire (Baxalta)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. CSL
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Grifols
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Octapharma
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Kedrion
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. LFB Group
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Biotest
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. BPL
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. RAAS
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. CBPO
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Hualan Bio
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Kamada
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Plasma Protein Therapeutic
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
